| Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial AO Kaseb, E Hasanov, HST Cao, L Xiao, JN Vauthey, SS Lee, BG Yavuz, ... The Lancet Gastroenterology & Hepatology 7 (3), 208-218, 2022 | 141 | 2022 |
| Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA AO Kaseb, NS Sánchez, S Sen, RK Kelley, B Tan, AG Bocobo, KH Lim, ... Clinical Cancer Research 25 (20), 6107-6118, 2019 | 69 | 2019 |
| Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 58 | 2020 |
| Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 55 | 2020 |
| Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 53 | 2021 |
| Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC A Kaseb, DG Duda, HST Cao, YI Abugabal, LM Vence, A Rashid, ... Annals of Oncology 30, v880, 2019 | 53 | 2019 |
| The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 51 | 2021 |
| Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score … B Marinelli, E Kim, A D'Alessio, M Cedillo, I Sinha, N Debnath, M Kudo, ... Journal for immunotherapy of cancer 10 (6), 2022 | 42 | 2022 |
| Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma P Fessas, M Naeem, M Pinter, TU Marron, D Szafron, L Balcar, A Saeed, ... Liver Cancer 10 (6), 583-592, 2021 | 39 | 2021 |
| Origin and role of hepatic myofibroblasts in hepatocellular carcinoma BG Yavuz, RC Pestana, YI Abugabal, S Krishnan, J Chen, MM Hassan, ... Oncotarget 11 (13), 1186, 2020 | 38 | 2020 |
| Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. AO Kaseb, HS Tran Cao, YI Mohamed, A Qayyum, LM Vence, JM Blando, ... Journal of Clinical Oncology 38 (15_suppl), 4599-4599, 2020 | 37 | 2020 |
| Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy DJ Pinato, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 26 | 2020 |
| Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma B Gok Yavuz, E Hasanov, SS Lee, YI Mohamed, MA Curran, EJ Koay, ... Journal of Hepatocellular Carcinoma, 1195-1207, 2021 | 24 | 2021 |
| Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma RC Pestana, MM Hassan, R Abdel-Wahab, YI Abugabal, LM Girard, D Li, ... Oncotarget 9 (102), 37721, 2018 | 20 | 2018 |
| Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study T Talbot, A D'Alessio, M Pinter, L Balcar, B Scheiner, TU Marron, T Jun, ... Liver International 43 (3), 695-707, 2023 | 19* | 2023 |
| The impact of angiotensin-converting enzyme 2 (ACE2) expression on the incidence and severity of COVID-19 infection AO Kaseb, YI Mohamed, AE Malek, II Raad, L Altameemi, D Li, OA Kaseb, ... Pathogens 10 (3), 379, 2021 | 19 | 2021 |
| HepatoScore‐14: measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk JS Morris, MM Hassan, YE Zohner, Z Wang, L Xiao, A Rashid, A Haque, ... Hepatology 73 (6), 2278-2292, 2021 | 16 | 2021 |
| Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma A Qayyum, P Bhosale, R Aslam, R Avritscher, J Ma, MD Pagel, J Sun, ... Abdominal Radiology 46, 1008-1015, 2021 | 13 | 2021 |
| Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells L Gu, Y Zhu, M Lee, A Nguyen, NT Ryujin, JY Huang, SK Pandit, ... Proceedings of the National Academy of Sciences 120 (19), e2300706120, 2023 | 12 | 2023 |
| Blockade of growth hormone receptor signaling by using pegvisomant: a functional therapeutic strategy in hepatocellular carcinoma AO Kaseb, A Haque, D Vishwamitra, MM Hassan, L Xiao, B George, ... Frontiers in Oncology 12, 986305, 2022 | 10 | 2022 |
Jeffrey S. MorrisUniversity of PennsylvaniaVerified email at pennmedicine.upenn.edu
